Vaccines against Flaviviruses and Alphaviruses: Recent Advances and Future Challenges

Dear Colleagues,

The mosquito-borne viruses such as Dengue (DENV), Zika (ZIKV) and Chikungunya (CHIKV) viruses have emerged in recent decades affecting millions of people worldwide. These flaviviruses and alphaviruses can be classified into a broader category of arboviruses, and they cause significant disease burdens and public health concerns. Vaccine development against arboviruses has experienced swift progress after the sudden (re)emergence of cases of DENV, CHIKV and ZIKV in the last two decades. Despite the fact that there are no licensed vaccines against ZIKV and CHIKV, the wide range of vaccine platforms including both classic and new approaches such as inactivated and attenuated, proteins, virus-like particles (VLPs), viral vectors, DNA and mRNA are currently being tested in pre-clinical studies and in clinical trials which could lead to the future licensing of vaccines.

This Special Issue will feature vaccines against flaviviruses and alphaviruses of medical importance in humans with a particular focus on the design, development and validation of new vaccine candidates and the animal model. We welcome the submission of all types of articles, including short reports, original research, and reviews for this issue. We look forward to receiving your contributions.

Dr. Young Chan Kim
Dr. Arturo Reyes-Sandoval
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.